In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
Effects of active commuting on exercise capacity, cardiovascular risk, body composition and quality of life: results of a randomized-controlled study
Authors : VA Rossi (Zurich,CH), B Reich (Salzburg,AT), MD Fernandez Lapuente De Battre (Salzburg,AT), P Stutz (Salzburg,AT), B Zagel (Salzburg,AT), M Loidl (Salzburg,AT), CM Schmied (Zurich,CH), J Niebauer (Salzburg,AT), D Niederseer (Zurich,CH)
MD Fernandez Lapuente De Battre2
1University Hospital Zurich, Department of Cardiology - Zurich - Switzerland
2Paracelsus Private Medical University - Salzburg - Austria
3University of Salzburg, Z_GIS - Salzburg - Austria
On behalf: GISMO (Geographical Information Support for Healthy Mobility)
Sedentary lifestyle is a major modifiable risk factor for cardiovascular diseases and triggers substantial costs due to early retirement and the inability to participate in the work force. Active commuting has been proposed to at least in part overcome these problems; however, convincing data to support this recommendation are sparse.
Purpose: To investigate the health effects of active commuting.
Methods: 73 subjects (age: 46±9 years, 38% males) were 2:1 randomized to an intervention group (IG, n=51) or control group (CG, n=22). Depending on the distance to the work place, IG participants either traveled by a combination of public transport and walking and/or cycling (n=25), or they commuted by walking and/or cycling only (n=26). The CG was asked to commute as usual. Exercise capacity, body composition, everyday physical activity, quality of life, and cardiovascular risk factors were assessed at baseline and after a study period of one year.
Results: Groups did not differ significantly at baseline. Daily self-reported commuting details were verified by GPS-tracking. Subjects randomized to IG changed their commuting habits, whereas CG did not (%time of commuting: IG: walking/cycling/public transport: 93%, car: 7%, CG: walking/cycling/public transport: 54%, car: 46%, p<0.001). Time to commute did not differ significantly. Percentage of age-predicted exercise capacity (IG: 145±25 to 155±31, p<0.001; CG: 142±25 to 136±25%, p=0.058; IG vs. CG: p=0.003) improved significantly in IG and remained unchanged in CG, whereas everyday physical activity (IG: 3756±4150 to 7092±6192, p<0.001; CG: 5251±5076 to 5609±4470 MET-min/week, p=0.539; IG vs. CG: p=0.067) improved significantly in IG and remained unchanged in CG, however the difference between groups only showed a statistical trend. In IG but not in CG subjects lost body fat (% of body weight: IG: 34.5±7.7 to 33.2±7.8%, p=0.003; CG: 35.0±9.1 to 34.8±7.4%; p=0.428; IG vs. CG: p=0.496), however no significant difference between groups was achieved. Cardiovascular risk profile assessed by HeartScore in these relatively healthy subjects remained essentially unchanged in both groups (p>0.05 for both groups). In quality of life assessment (SF-36), general health (p=0.008), vitality (p=0.003) and mental health (p=0.012) changed significantly in IG, whereas no significant changes were noted in CG (p>0.05, IG vs. CG: all p<0.001). No serious adverse events occurred during the study.
Conclusion: Our results indicate that active commuting to work may counteract certain downsides of a sedentary lifestyle without prolonging the time-period of the commuting to work substantially.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease